Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727886 | 0.82 | — | — | |
| SCHEMBL8917128 | 0.80 | — | — | |
| SCHEMBL250780 | 0.78 | — | — | |
| SCHEMBL629559 | 0.77 | TSHR (0.37) | TSHRHCAR2 | |
| SCHEMBL8918944 | 0.76 | LMNA (0.39) | — | |
| SCHEMBL1100387 | 0.74 | ALDH1A1 (0.40) | TSHR | |
| SCHEMBL5872657 | 0.74 | TSHR (0.34) | TSHR | |
| SCHEMBL7400438 | 0.74 | — | — | |
| SCHEMBL8982387 | 0.73 | TSHR (0.42) | TSHR | |
| SCHEMBL3883972 | 0.73 | CA12 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-7968707-B2 | Reacting an amino, hydroxy substituted amide with a heterocyclic substituted carboxylic acid to produce (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl) amino-3-hydroxy-5-[2S-1-imidazolidin-2-onyl)-3-methyl-butanoyl] amino-1,6-diphenylhexane; inhibitors of HIV infection | ABBOTT LABORATORIES (US) | 2011-06-28 | — | — | US | disclosed |
| US-20080139811-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBVIE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20030216258-A1 | Condensed heterocylic compounds and herbicides containing them as active ingredients | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-11-20 | — | — | US | disclosed |
| US-6586368-B1 | Benzofuran derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1112268-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AND HERBICIDES CONTAINING THEM | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015633-A1 | CONDENSED HETEROCYLIC COMPOUNDS AND HERBICIDES CONTAINING THEM | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-03-23 | — | — | WO | disclosed |
| US-5637255-A | OPTICALLY ACTIVE FORM, USED FOR OPTICAL OR ELECTROOPTICAL DISPLYING; HIGH TWISTING; DOPANT | ROLIC AG (CH) | 1997-06-10 | — | — | US | disclosed |
| US-5360577-A | MIXTURE OF OPTICALLY ACTIVE OXAZOLINE COMPOUND AND A LIQUID CRYSTALLINE CARRIER | HOFFMANN-LA ROCHE INC. (US) | 1994-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | PSMG3, PSME1, PSMB1 | TSHR 4697/4885HCAR2 3888/4885 |
| US-20080139811-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | SERPINB1, PREP, DNPEP | TSHR 4756/4885HCAR2 4775/4885 |
| US-20030216258-A1 | Condensed heterocylic compounds and herbicides containing them as active ingredients | CBR3, CBR1, HAAO | TSHR 1858/4885HCAR2 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.